Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

NCT: NCT05799664 · RECRUITING

NCT IDNCT05799664
StatusRECRUITING
Start Date2023-07-04
Completion2028-06
SponsorHangzhou Broncus Medical Co., Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.

Frequently Asked Questions

What is Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD?

Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD is a clinical trial registered under NCT05799664. Current status: RECRUITING.

What is the status of NCT05799664?

The current status of NCT05799664 (Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD) is: RECRUITING.

When did Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD start?

Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD started on 2023-07-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑